The future of fibroblast growth factor receptor inhibitors and mechanisms of resistance for cholangiocarcinoma

References

• Chmiel P, Gęca K, Rawicz-Pruszyński K, et al. FGFR inhibitors in Cholangiocarcinoma—A novel yet primary approach: where do we stand now and where to head next in targeting this axis? Cells. 2022;11(23):3929. DOI:10.3390/cells11233929
   PubMedGoogle Scholar
• Goyal L, Kongpetch S, Crolley VE, et al. Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat Rev. 2021;95:102170.
   PubMed Web of Science ®Google Scholar
• Esnaola NF, Meyer JE, Karachristos A, et al. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer. 2016;122(9):1349–1369. DOI:10.1002/cncr.29692
   PubMed Web of Science ®Google Scholar
• Cardinale V, Semeraro R, Torrice A, et al. Intra-hepatic and extra-hepatic cholangiocarcinoma: new insight into epidemiology and risk factors. World J Gastrointest Oncol. 2010;2(11):407–416. DOI:10.4251/wjgo.v2.i11.407
   PubMedGoogle Scholar
• Patel N, Benipal B. Incidence of Cholangiocarcinoma in the USA from 2001 to 2015: a US cancer statistics analysis of 50 states. Cureus. 2019;11(1):e3962.
   PubMed Web of Science ®Google Scholar
• Alabraba E, Joshi H, Bird N, et al. Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged. Eur J Surg Oncol. 2019;45(9):1660–1667. DOI:10.1016/j.ejso.2019.04.002
   PubMed Web of Science ®Google Scholar
• Gad MM, Saad AM, Faisaluddin M, et al. Epidemiology of Cholangiocarcinoma; United States incidence and mortality trends. Clin Res Hepatol Gastroenterol. 2020;44(6):885–893. DOI:10.1016/j.clinre.2020.03.024
   PubMed Web of Science ®Google Scholar
• Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95–111. DOI:10.1038/nrclinonc.2017.157
   PubMed Web of Science ®Google Scholar
• Lowery MA, Ptashkin R, Jordan E, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic Cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24(17):4154–4161. DOI:10.1158/1078-0432.CCR-18-0078
   PubMed Web of Science ®Google Scholar
• Javle M, Bekaii-Saab T, Jain A, et al. Biliary cancer: utility of next-generation sequencing for clinical management. Cancer. 2016;122(24):3838–3847. DOI:10.1002/cncr.30254
   PubMed Web of Science ®Google Scholar
• Zingg D, Bhin J, Yemelyanenko J, et al. Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature. 2022;608(7923):609–617. DOI:10.1038/s41586-022-05066-5
   PubMed Web of Science ®Google Scholar
• Helsten T, Elkin S, Arthur E, et al. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res. 2016;22(1):259–267. DOI:10.1158/1078-0432.CCR-14-3212
   PubMed Web of Science ®Google Scholar
• Lamarca A, Edeline J, Goyal L. How I treat biliary tract cancer. ESMO Open. 2022;7(1):100378.
   PubMed Web of Science ®Google Scholar
• Goyal L, Lamarca A, Strickler JH, et al. The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA). J Clin Oncol. 2020;38(15_suppl):e16686-e. DOI:10.1200/JCO.2020.38.15_suppl.e16686
   Google Scholar
• Jain A, Borad MJ, Kelley RK, et al. Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype. JCO Precision Oncol. 2018;2018(2):1–12. DOI:10.1200/PO.17.00080
   Google Scholar
• Cleary JM, Raghavan S, Wu Q, et al. FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in Cholangiocarcinoma. Cancer Discov. 2021;11(10):2488–2505. DOI:10.1158/2159-8290.CD-20-1669
   PubMed Web of Science ®Google Scholar
• Ellinghaus P, Neureiter D, Nogai H, et al. Patient selection approaches in FGFR inhibitor trials—Many paths to the same end? Cells. 2022;11(19):3180. DOI:10.3390/cells11193180
   PubMedGoogle Scholar
• King G, Javle M. FGFR inhibitors: clinical activity and development in the treatment of Cholangiocarcinoma. Curr Oncol Rep. 2021;23(9):108.
   PubMedGoogle Scholar
• Zheng J, Zhang W, Li L, et al. Signaling pathway and small-molecule drug discovery of FGFR: a Comprehensive review. Front Chem. 2022;10:860985.
   PubMedGoogle Scholar
• Voss MH, Hierro C, Heist RS, et al. A phase i, open-label, multicenter, dose-escalation study of the oral selective FGFR inhibitor debio 1347 in patients with advanced solid tumors harboring FGFR gene alterations. Clin Cancer Res. 2019;25(9):2699–2707. DOI:10.1158/1078-0432.CCR-18-1959
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, El-Rayes BF, Droz Dit Busset M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019;120(2):165–171. DOI:10.1038/s41416-018-0334-0
   PubMed Web of Science ®Google Scholar
• Javle MM, Abou-Alfa GK, Macarulla T, et al. Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: interim results from the phase 2 study FIDES-01. J Clin Oncol. 2022;40(4_suppl):427. DOI:10.1200/JCO.2022.40.4_suppl.427
   PubMedGoogle Scholar
• Rizzo A. Targeted therapies in advanced Cholangiocarcinoma: a focus on FGFR inhibitors. Med (Kaunas). 2021;57(5):458.
   PubMedGoogle Scholar
• Park JO, Feng Y-H, Chen Y-Y, et al. Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations. J Clin Oncol. 2019;37(15_suppl):4117. DOI:10.1200/JCO.2019.37.15_suppl.4117
   Web of Science ®Google Scholar
• Loriot Y, Schuler MH, Iyer G, et al. Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: interim analysis (IA) results. J Clin Oncol. 2022;40(16_suppl):3007. DOI:10.1200/JCO.2022.40.16_suppl.3007
   Web of Science ®Google Scholar
• Pant S, Schuler MH, Iyer G, et al. Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase 2 open-label, single-arm RAGNAR trial: expansion cohort results. J Clin Oncol. 2023;41(4_suppl):610. DOI:10.1200/JCO.2023.41.4_suppl.610
   Google Scholar
• Javle M, Roychowdhury S, Kelley RK, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021;6(10):803–815. DOI:10.1016/S2468-1253(21)00196-5
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. Expert Opin Investig Drugs. 2021;30(4):317–324.
   PubMed Web of Science ®Google Scholar
• Sootome H, Fujita H, Ito K, et al. Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-Deregulated tumors. Cancer Res. 2020;80(22):4986–4997. DOI:10.1158/0008-5472.CAN-19-2568
   PubMed Web of Science ®Google Scholar
• Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2-rearranged intrahepatic Cholangiocarcinoma. N Engl J Med. 2023;388(3):228–239. DOI:10.1056/NEJMoa2206834
   PubMed Web of Science ®Google Scholar
• Subbiah V, Iannotti NO, Gutierrez M, et al. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Ann Oncol. 2022;33(5):522–533. DOI:10.1016/j.annonc.2022.02.001
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–684. DOI:10.1016/S1470-2045(20)30109-1
   PubMed Web of Science ®Google Scholar
• Zugman M, Botrus G, Pestana RC, et al. Precision medicine targeting FGFR2 genomic alterations in advanced Cholangiocarcinoma: current state and future perspectives. Front Oncol. 2022;12:860453.
   PubMedGoogle Scholar
• Schram AM, Kamath SD, El-Khoueiry AB, et al. First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors. J Clin Oncol. 2021;39(15_suppl):TPS4165-TPS. DOI:10.1200/JCO.2021.39.15_suppl.TPS4165
   PubMedGoogle Scholar
• Hollebecque A, Borad M, Goyal L, et al. Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial. 2022 2/9/23]; Available from: https://oncologypro.esmo.org/meeting-resources/esmo-congress/efficacy-of-rly-4008-a-highly-selective-fgfr2-inhibitor-in-patients-pts-with-an-fgfr2-fusion-or-rearrangement-f-r-fgfr-inhibitor-fgfri-naiv.
   Google Scholar
• Krook MA, Reeser JW, Ernst G, et al. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br J Cancer. 2021;124(5):880–892. DOI:10.1038/s41416-020-01157-0
   PubMed Web of Science ®Google Scholar
• Bai A, Meetze K, Vo NY, et al. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res. 2010;70(19):7630–7639. DOI:10.1158/0008-5472.CAN-10-1489
   PubMed Web of Science ®Google Scholar
• Sommer A, Kopitz C, Schatz CA, et al. Preclinical Efficacy of the auristatin-based antibody-drug conjugate BAY 1187982 for the treatment of FGFR2-positive solid tumors. Cancer Res. 2016;76(21):6331–6339. DOI:10.1158/0008-5472.CAN-16-0180
   PubMed Web of Science ®Google Scholar
• Kim SB, Meric-Bernstam F, Kalyan A, et al. First-in-human phase i study of aprutumab ixadotin, a fibroblast growth factor receptor 2 antibody-drug conjugate (BAY 1187982) in patients with advanced cancer. Target Oncol. 2019;14(5):591–601. DOI:10.1007/s11523-019-00670-4
   PubMed Web of Science ®Google Scholar
• Hollebecque A, Silverman I, Owens S, et al. 720P - Comprehensive genomic profiling and clinical outcomes in patients (pts) with fibroblast growth factor receptor rearrangement-positive (FGFR2+) cholangiocarcinoma (CCA) treated with pemigatinib in the fight-202 trial. Ann Oncol. 2019;30:v276.
   Web of Science ®Google Scholar
• Lau DK, Jenkins L, Weickhardt A. Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapy. Cancer Drug Resist. 2019;2(3):568–579.
   PubMedGoogle Scholar
• Kitano S, Yamamoto T, Taketo MM. Novel parameter for cancer chemosensitivity to fibroblast growth factor receptor inhibitors. Cancer Sci. 2022;113(11):4005–4010.
   PubMed Web of Science ®Google Scholar
• Wu Q, Zhen Y, Shi L, et al. EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion-positive Cholangiocarcinoma. Cancer Discov. 2022;12(5):1378–1395. DOI:10.1158/2159-8290.CD-21-1168
   PubMed Web of Science ®Google Scholar
• Varghese AM, Patel JAA, Janjigian YY, et al. Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations. J Clin Oncol. 2019;37(15_suppl):4096. DOI:10.1200/JCO.2019.37.15_suppl.4096
   Google Scholar
• Goyal L, Saha SK, Liu LY, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion–positive Cholangiocarcinoma. Cancer Discovery. 2017;7(3):252–263. DOI:10.1158/2159-8290.CD-16-1000
   PubMed Web of Science ®Google Scholar
• Varghese AM, Patel J, Janjigian YY, et al. Noninvasive detection of polyclonal acquired resistance to FGFR inhibition in patients with Cholangiocarcinoma harboring FGFR2 alterations. JCO Precis Oncol. 2021;5(5):44–50. DOI:10.1200/PO.20.00178
   Google Scholar
• Goyal L, Shi L, Liu LY, et al. TAS-120 overcomes resistance to ATP-Competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic Cholangiocarcinoma. Cancer Discov. 2019;9(8):1064–1079. DOI:10.1158/2159-8290.CD-19-0182
   PubMed Web of Science ®Google Scholar
• Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–673. DOI:10.1016/S1470-2045(18)30915-X
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281. DOI:10.1056/NEJMoa0908721
   PubMed Web of Science ®Google Scholar
• Oh D-Y, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evidence. 2022;1(8):EVIDoa2200015. DOI:10.1056/EVIDoa2200015
   PubMedGoogle Scholar